Beijing Knowing Genes Biomedical Technology Co., Ltd. has proudly announced the successful completion of its seed round financing, raising tens of millions of yuan. This round was exclusively led by Shaanxi Growth Enterprise Guidance Fund Management Co., Ltd. The funds raised will be strategically allocated to support preclinical research on key product pipelines, the submission of Investigational New Drug (IND) applications, the establishment of a Good Manufacturing Practice (GMP) laboratory, and the procurement of essential equipment. These efforts are geared towards expediting the clinical translation of cellular reprogramming technology.

The core team at Knowing Genes boasts a wealth of research expertise in cellular reprogramming, complemented by hands-on industrialization experience gained from working with leading cell therapy companies. The company has independently developed the iCellFate cellular fate programming operating system, showcasing its mastery over a variety of differentiated underlying technologies. Employing a dual-engine pipeline strategy that combines "high-value tumor immunotherapy with high-demand regenerative medicine," Knowing Genes has laid out multiple product pipelines. These include NKaT therapy, corneal cell repair, and hair follicle regeneration, among others.

Both the team at Knowing Genes and its investors are brimming with confidence in the promising future of the cellular reprogramming sector and the company's technological edge. With this seed funding, Knowing Genes is poised to make significant strides in advancing cellular reprogramming technology and bringing innovative therapies to the forefront of medical science.